Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7834653 | 0.88 | PSEN1 (0.61) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8149129 | 0.86 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8142330 | 0.86 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL12845546 | 0.86 | PSEN1 (0.59) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL29940580 | 0.85 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL758550 | 0.85 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL909160 | 0.85 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL909159 | 0.85 | PSEN1 (0.58) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3125879 | 0.84 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL909275 | 0.84 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-8183276-B2 | Therapeutic agents | MERCK SHARP & DOHME CORP. | 2012-05-22 | — | — | US | disclosed |
| US-7935815-B2 | Imidazoyl pyridine compounds and salts thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| US-20110009619-A1 | POLYCYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20100324029-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME CORP. | 2010-12-23 | — | — | US | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009619-A1 | POLYCYCLIC COMPOUND | APP, BACE1, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 9/4885 |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | PSEN1 2/4885PSEN2 5/4885APH1B 36/4885 |
| US-20100324029-A1 | THERAPEUTIC AGENTS | PSEN2, PSEN1, BACE2 | PSEN1 2/4885PSEN2 1/4885APH1B 20/4885 |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 7/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.